Ascelia: A re-evaluation is required of the SPARKLE study - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Ascelia: A re-evaluation is required of the SPARKLE study - Redeye

{newsItem.title}

The ordinary required revaluation of a certain number of patients showed a high level of variability. This unexpected high level of intra-reader inconsistency will require a re-evaluation by a new group of independent radiology readers. Ascelia plan to give a new update regarding the timelines and the financial implications by mid-September. Our Base Case is obviously under review.

Länk till analysen i sin helhet: https://www.redeye.se/research/928404/ascelia-a-re-evaluation-is-required-of-the-sparkle-study?utm_source=finwire&utm_medium=RSS

Nyheter om Ascelia Pharma

Läses av andra just nu

Om aktien Ascelia Pharma

Senaste nytt